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in 38% of ischemic stroke patients (46% in Germany vs 22% in
Spain). CONCLUSIONS: These data are showing that statins are
widely used in the acute setting with signiﬁcant differences across
Europe.
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OBJECTIVES: STEMI patients (pts) presenting <12 h since onset
of symptoms should receive reperfusion therapy, which results in
important mortality reduction. However, critical presentation
timing is not the only factor that inﬂuences treatment choice for
STEMI pts. In this study we assess the scale at which clinical
guidelines are followed in the treatment of STEMI patients
presenting within the timeframe of reperfusion therapy.
METHODS: This was a retrospective patient diary study using
the IMS Health Acute Cardiovascular Analyzer. The study was
conducted in 264 hospitals with Cath-Lab facilities in France,
Germany, Italy, Spain and UK. They treated a total of 2553
patients diagnosed with STEMI, during the period of August
2006 and April 2007, with a mean of 10 patients per hospital.
Hospitals were selected to be representative by geographic
regions, size and facilities in each country. We analysed the data
to determine factors associated with patients not receiving rep-
erfusion therapy. RESULTS: We found 2333 (91%) pts were
admitted within 12 hours of onset of symptoms, where 49% had
primary PCI, 16% received thrombolytics, 15% received throm-
bolytics and PCI, 8% had PCI outside the 12 hours reperfusion
window, 9% didn’t receive PCI neither thrombolytics, 2% had
CABG: We report data from 393 patients who didn’t receive
reperfusion therapy and accounts for patients not receiving
primary PCI or thrombolytics: 66% had dyslipidaemia, 63%
hypertension, 37% CHF, 30% diabetes, 19% age >80, 12%
stable angina and 11% with PAD. Also, it was noted that 40% of
these patients experienced delay in-hospital diagnosis, and thus
haven’t received reperfusion therapy within the 12 hours
window, 10% were contraindicated to thrombolytics, and 39%
were scheduled to receive revascularisation. In-hospital mortality
accounted for 14% of the total untreated population. CONCLU-
SION: This study concludes that 17% of STEMI patients admit-
ted to Cath Lab hospitals within 12 hours of onset of symptoms
in Europe don’t receive reperfusion therapy even when catheral-
ization facilities are available.
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OBJECTIVES: Different statin dose titration and treatment
switching strategies of atorvastatin, rosuvastatin, and simvasta-
tin were compared in the Swedish setting. The objective was to
ﬁnd the optimal treatment mix strategy (i.e. a mix that provides
the greatest beneﬁts in terms of cost (€ in 2008 value) per patient
treated to target (PTT)) in high-risk patients with elevated LDL-
cholesterol (LDL-C). METHODS: A decision-analytic model
with Monte Carlo simulation was developed to estimate the
expected net beneﬁts of different statin treatment mix strategies.
Since it has been demonstrated that the optimal option may not
always have the highest probability of being cost-effective for a
given value of cost-effectiveness threshold (l), a new approach,
named the optimal treatment mix chart (OTMC), was devel-
oped. The OTMC is based on cost-effectiveness acceptability
frontiers (CEAF). RESULTS: In the base case (LDL-
C = 4.42 mmol/l) and when l < €350/PTT, the optimal option
was to initiate treatment with simvastatin 10 mg and to titrate
dose up to the assumed maximum tolerated dose (40 mg) until
the treatment target (LDL-C  2.5 mmol/l) was reached. When
€350 < l < €775, the optimal option was to initiate a treatment
mix, where simvastatin was up-titrated to 40 mg and then
switched to a higher-potency statin (here rosuvastatin), when
needed. When l > 775€ the optimal option was to initiate a
treatment with simvastatin 20 mg and then directly switch to
rosuvastatin, when needed. CONCLUSIONS: The selection of
the optimum treatment mix is conditional on baseline assump-
tions. OTMC provides a natural and practical graphic tool for
presenting the optimal treatment mix at different l-values under
different baseline assumptions (e.g. different baseline LDL-C
levels). The majority of Swedish patients will, currently and in
real-life, not generally experience dose titration and/or change of
statin after treatment initiation. Therefore, rosuvastatin has a
central role in a treatment “mix” for high risk patients with the
LDL-C exceeding 4.2 mmol/l.
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OBJECTIVES: To contain health care expenditure, the Korean
National Health Insurance (NHI) sets reimbursement criteria for
lipid-lowering therapy that are quite strict. We assessed the
potential health and economic effects of relaxing the criteria for
lipid-lowering treatment in Korea to align with NCEP-ATPIII
recommendations. METHODS: A microsimulation Markov
model was constructed with yearly cycles and the health states
‘Alive without cardiovascular disease (CVD)’, ‘Alive with CVD’,
‘Dead from CVD’ and ‘Dead from non-CVD causes’. It was
populated with CVD-naïve subjects aged 55 years from the
nationally-representative 2005 Korean NHANES. Follow-up
until death or age 99 years was simulated. An Asian-speciﬁc risk
equation (Wu 2006) was applied to estimate cardiovascular risks.
Sex-and-age-speciﬁc mortality risks were drawn from national
health statistics. Decision analysis compared treatment according
to the two sets of criteria. Eligible patients were all prescribed
atorvastatin, the lipid-modifying efﬁcacy and costs of which were
drawn from a meta-analysis and current drug pricing schedules,
respectively. CVD cost estimates were provided by the Korean
Health Insurance Review and Assessment Services. A ﬁve percent
annual discount rate was applied. RESULTS: Nearly three times
more Koreans aged 55 years would quality for lipid-lowering
therapy if NCEP-ATPIII instead of NHI criteria were to be
applied (43.1% vs 15.0%). Compared to treatment under NHI
criteria, the treatment of 1000 Koreans aged 55 years under
NCEP-ATPIII criteria would lead to 38 less cardiovascular events
(447 vs 409) and 3195 more QALYs (10,843 vs 7648) over a
lifetime. There would be saving of 845 million KW in net costs
(9876 vs 10,721 million). CONCLUSIONS: Current criteria for
lipid-lowering therapy in Korea are conservative. If NCEP-
ATPIII criteria were to be adopted, as in many other countries,
signiﬁcantly more patients would qualify for treatment, but the
strategy would represent a more effective and cost-effective way
of preventing CVD.
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